Professor Cao Xinping is a  chief physician and clinical professor of Radiation Oncology at Sun Yat-sen University Cancer Center (SYSUCC). With a career spanning over three decades, Professor Cao has established himself as a leading expert in the field of gynecological oncology and brachytherapy (internal radiation therapy). He is a mentor for both master's and postdoctoral students.
Professor Cao graduated from Sun Yat-sen University Medical College in 1986 and has since dedicated his career to the Department of Radiation Oncology at SYSUCC. He completed his master's and doctoral studies at the same institution, further solidifying his expertise in cancer treatment. His primary focus lies in the radiation therapy of gynecological cancers, particularly cervical cancer, where he has pioneered several advanced brachytherapy techniques. Notably, he performed the first cases of 3D image-guided high-dose-rate interstitial brachytherapy for cervical, nasopharyngeal, prostate, and breast cancers in China.
In addition to his clinical work, Professor Cao is actively involved in academic and professional organizations. He serves as the Chairman of the Brachytherapy Committee of the Chinese Anti-Cancer Association and holds leadership roles in several national and regional oncology societies. His research has been widely published, with numerous articles in high-impact journals such as Cell Death and Differentiation, Cancer, and Radiation Oncology. He has also authored and co-authored several influential textbooks on brachytherapy and gynecological cancer treatment.
Professor Cao's contributions to the field have been recognized with numerous awards, including the Guangdong Medical Association Excellence Award in 2023 for his innovative work in developing multi-channel vaginal molds for brachytherapy. His ongoing research continues to push the boundaries of cancer treatment, particularly in improving the precision and efficacy of radiation therapy for gynecological malignancies.

Radiotherapy for gynecologic tumor  (such as: cervical cancer, endometrial cancer, carcinoma of vulva, ovarian cancer)
Brachytherapy (such as: cervical cancer, nasopharyngeal carcinoma, prostate cancer, breast cancer)

Bachelor's Degree, Sun Yat-Sen University of Medical college, China,1980-1986

Master's Degree, Sun Yat-Sen University of Medical college, China,1999-1998

Doctor's Degree, Sun Yat-Sen University of Medical college, China,1998-2001

1.Wu H, Huang L, Chen X, OuYang Y, Li J, Chen K, Huang X, Chen F, Cao X. Establishment of a Novel Risk Stratification System Integrating Clinical and Pathological Parameters for Prognostication and Clinical Decision-Making in Early-Stage Cervical Cancer. Cancer Med. 2024 Nov;13(22):e70394. doi: 10.1002/cam4.70394. 
2.Huang X, Huo L, Xiao B, Ouyang Y, Chen F, Li J, Zheng X, Wei D, Wu Y, Zhang R, Cao X, Kang T, Gao Y. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. Cell Death Differ. 2024 Jan;31(1):78-89. doi: 10.1038/s41418-023-01242-w. 
3.Shi L, Liu Y, Li J, Kou J, Ouyang Y, Chen F, Huang X, Huo L, Huang L, Cao X. Establishment of a risk stratification model based on the combination of post-treatment serum squamous cell carcinoma antigen levels and FIGO stage of cervical cancer for treatment and surveillance decision-making. J Cancer Res Clin Oncol. 2023 Aug;149(9):5999-6007. doi: 10.1007/s00432-022-04558-1. 
4.Li J, Huang L, Wu H, Li J, Cao X, Liu Z. Re-irradiation for recurrent cervical cancer: A single institutional experience. Clin Transl Radiat Oncol. 2023;43:100690. Published 2023 Oct 10. doi:10.1016/j.ctro.2023.100690
5.Huang XD, Chen K, Shi L, Luo YS, Ou-Yang Y, Li JY, Huo LQ, Huang L, Chen FP, Cao XP. Construction of refined staging classification systems integrating FIGO/T-categories and corpus uterine invasion for non-metastatic cervical cancer. Cancer Med. 2023 Jul;12(14):15079-15089. doi: 10.1002/cam4.6179.
6.Huang H, Nie CP, Liu XF, Song B, Yue JH, Xu JX, He J, Li K, Feng YL, Wan T, Zheng M, Zhang YN, Ye WJ, Li JD, Li YF, Li JY, Cao XP, Liu ZM, Zhang XS, Liu Q, Zhang X, Liu JH, Li J. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest. 2022 Aug 1;132(15):e157726. doi: 10.1172/JCI157726. 
7.Chen FP, Luo YS, Chen K, Li JY, Huo LQ, Shi L, Ou-Yang Y, Cao XP. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma. Eur J Cancer. 2021 Jul;151:63-71. doi: 10.1016/j.ejca.2021.03.052.
8.Huang H, Feng YL, Wan T, Zhang YN, Cao XP, Huang YW, Xiong Y, Huang X, Zheng M, Li YF, Li JD, Chen GD, Li H, Chen YL, Ma LG, Yang HY, Li L, Yao SZ, Ye WJ, Tu H, Huang QD, Liang LZ, Liu FY, Liu Q, Liu JH. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Mar 1;7(3):361-369. doi: 10.1001/jamaoncol.2020.7168. 
9.Li J, Ouyang Y, Tao Y, Wang L, Li M, Gao L, Cao X. Small cell carcinoma of the uterine cervix: a multi-institutional experience. Int J Gynecol Cancer. 2020 Feb;30(2):174-180. doi: 10.1136/ijgc-2019-000612.
10.Wang Y, Ouyang Y, Su J, Liu J, Cai Q, Xu Q, Bai Z, Cao X. Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol. BMJ Open. 2019 Oct 7;9(10):e028171. doi: 10.1136/bmjopen-2018-028171. 
11.Lin Y, Ouyang Y, Chen K, Lu Z, Liu Y, Cao X. Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience. Front Oncol. 2019 Aug 16;9:760. doi: 10.3389/fonc.2019.00760. 
12.Lin Y, Zhai H, Ouyang Y, Lu Z, Chu C, He Q, Cao X. Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells. Cancer Cell Int. 2019 May 14;19:129. doi: 10.1186/s12935-019-0845-7.
13.Lin Y, Ouyang Y, Lu Z, Liu Y, Chen K, Cao X. Long-Term Outcomes of Three-Dimensional High-Dose-Rate Brachytherapy for Locally Recurrent Early T-Stage Nasopharyngeal Carcinoma. Front Oncol. 2019 Apr 26;9:278. doi: 10.3389/fonc.2019.00278. 
14.Lin Y, Meng F, Lu Z, Chen K, Tao Y, Ouyang Y, Cao X. Knockdown of PKM2 suppresses tumor progression in human cervical cancer by modulating epithelial-mesenchymal transition via Wnt/β-catenin signaling. Cancer Manag Res. 2018 Oct 4;10:4191-4202. doi: 10.2147/CMAR.S178219. 
15.Lin Y, Chen K, Lu Z, Zhao L, Tao Y, Ouyang Y, Cao X. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol. 2018 Sep 14;13(1):177. doi: 10.1186/s13014-018-1126-7.